veracyte. 2/22/2023 1 Q4 and Full-Year 2022 Business and Financial Presentation February 22, 2023 © Veracyte, Inc. All rights reserved. Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue for 2023 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our tests and products. Forward-looking statements can be identified by words su ...

Start Time: 16:30 January 1, 0000 5:29 PM ET Veracyte, Inc. (NASDAQ:VCYT) Q4 2022 Earnings Conference Call February 22, 2023, 16:30 PM ET Company Participants Marc Stapley - CEO Rebecca Chambers - EVP and CFO Tina Nova - President, U.S. CLIA Business Shayla Gorman - Director, IR Conference Call Participants Andrew Brackman - William Blair Dave Delahunt - Goldman Sachs Puneet Souda - SVB Securities Mason Carrico - Stephens, Inc Mike Matson - Needham & Company Yuko Oku - Morgan Stanley Andrew Cooper - Raymond ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Veracyte, Inc. (NASDAQ:VCYT) Q3 2022 Earnings Conference Call November 2, 2022 4:30 AM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Executive Vice President and Chief Financial Officer Tina Nova - President, U.S. CLIA Business Conference Call Participants Jacob Johnson - Stephens Griffin Soriano - William Blair Mike Matson - Needham & Company Hugo Leo - Morgan Stanley David Hein - Goldman Sachs Operator Good day, and thank y ...

Q3 2022 Business and Financial Presentation November 2, 2022 11/2/2022 © Veracyte, Inc. All rights reserved. 1 Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Sw ...

veracyte. Q2 2022 Business and Financial Presentation August 2, 2022 8/2/2022 © Veracyte, Inc. All rights reserved. 1 Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta N ...

Business Expansion and Acquisitions - Veracyte reported a significant expansion in its genomic testing menu with the acquisition of Decipher Biosciences, enhancing capabilities in urologic cancers [122]. - The acquisition of HalioDx in August 2021 allowed Veracyte to manufacture its own IVD test kits, strengthening its position in immuno-oncology [123]. - The integration of acquired assets from Decipher Biosciences and HalioDx may impact revenue growth and operational results as functions are consolidated [130]. Financial Performance - Total revenue for the three months ended June 30, 2022, was $72.864 million, representing a 32% increase compared to $55.105 million in the same period of 2021 [155]. - Testing revenue increased by 18% to $59.718 million for the three months ended June 30, 2022, compared to $50.793 million in the same period of 2021 [155]. - Biopharmaceutical and other revenue surged by 518% to $10.038 million for the three months ended June 30, 2022, compared to $1.624 million in the same period of 2021 [155]. - The company reported a net loss of $9.532 million for the three months ended June 30, 2022, a 5% increase from a net loss of $9.038 million in the same period of 2021 [155]. - The company recorded a net loss of $24.0 million for the six months ended June 30, 2022, with an accumulated deficit of $381.2 million as of the same date [174]. Testing Volume and Revenue - Total test volume increased by 19% to 24,904 tests for the three months ended June 30, 2022, compared to 20,856 tests in the same period of 2021 [155]. - Revenue increased by $17.8 million for the three months ended June 30, 2022, primarily due to a $8.9 million increase in testing revenue driven by a 19% volume increase in diagnostic tests [157]. - For the six months ended June 30, 2022, revenue increased by $48.8 million, with a $31.8 million increase in testing revenue driven by a 40% volume increase in diagnostic tests [158]. Expenses and Costs - Research and development expenses rose by 50% to $9.377 million for the three months ended June 30, 2022, compared to $6.249 million in the same period of 2021 [155]. - Selling and marketing expenses increased by 22% to $24.001 million for the three months ended June 30, 2022, compared to $19.662 million in the same period of 2021 [155]. - General and administrative expenses increased by $4.3 million (28%) for the three months ended June 30, 2022, compared to the same period in 2021, primarily due to compensation related to the acquisition of HalioDx and headcount additions [168]. - Compensation expense in research and development increased by 44% for the three months ended June 30, 2022, reflecting higher headcount and annual compensation increases [163]. Cash Flow and Financial Position - Cash used in operating activities for the six months ended June 30, 2022, was $9.2 million, a significant decrease from $38.7 million in the same period in 2021 [182]. - Cash used in investing activities for the six months ended June 30, 2022, was $11.8 million, compared to $574.1 million in the same period in 2021, which included the acquisition of Decipher Biosciences [186]. - Cash provided by financing activities for the six months ended June 30, 2022, was $1.9 million, a sharp decline from $592.9 million in the same period in 2021, which was primarily from a public offering [188]. - The company expects its existing cash and cash equivalents of $164.0 million as of June 30, 2022, to be sufficient to meet anticipated cash requirements for at least the next 12 months [175]. Market and Operational Challenges - The company has faced challenges in test volumes due to COVID-19, particularly affecting tests that require hospital procedures, such as Percepta and Envisia [125]. - Veracyte's Decipher Prostate test remained resilient during the pandemic, primarily due to its customer base being community-based urology practices [125]. - The company is facing inflation headwinds in compensation, travel, and supply costs, but does not believe inflation has materially affected its business or financial condition [194]. Research and Development - The company expects significant research and development expenses as it continues to invest in developing additional products and evaluating various platforms [148]. - The operations of HalioDx contributed approximately $8.8 million to the cost of biopharmaceutical and other revenue for the six months ended June 30, 2022 [162]. - Research and development expenses rose by $3.1 million, or 50%, for the three months ended June 30, 2022, with HalioDx operations contributing approximately $2.2 million to this increase [163]. Reimbursement and Revenue Recognition - Revenue growth is contingent on securing broader reimbursement from third-party payers and expanding the base of prescribing physicians [129]. - The average reimbursement rates for tests are subject to change based on payer coverage decisions and contractual agreements [137]. - Veracyte's testing revenue is recognized upon completion of tests, with billing occurring at the time results are delivered [133].

Veracyte, Inc. (NASDAQ:VCYT) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Tina Nova - President of CLIA Business Giulia Kennedy - Global Chief Scientific Officer and Chief Medical Officer Conference Call Participants Brian Weinstein - William Blair Puneet Souda - SVB Securities Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Andrew Coope ...

(veracyte. Q1 2022 Business & Financial Presentation May 3, 2022 Disclaimer This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Swab, Percepta Genomic Atlas and Decipher Bladder tests and prod ...

Veracyte, Inc. (NASDAQ:VCYT) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Giulia Kennedy – Chief Scientific & Medical Officer Tina Nova – General Manager of Thyroid & Urologic Cancer Sheila Goldman – Director of Investor Relations Conference Call Participants Brian Weinstein – William Blair David Hein – Goldman Sachs Mason Carrico – Stephens Inc. Tejas Savant – Morgan Stanley Paul Knight – KeyBa ...